Conmed’s 2.2 percent convertible notes are funding the transaction, according to a June 13 news release. In2Bones’ portfolio includes implants, fracture systems and biologic products.
The deal was announced in May. The acquisition includes up to an additional $110 million in growth-based earnout payments over four years.
